Affimed Therapeutics Raises Series B

Affimed Therapeutics AG, a Heidelberg, Germany-based developer of antibody therapeutics, has raised EUR 25 million in Series B funding. Participants included BioMedInvest, OrbiMed Advisors, Life Sciences Partners and return backer FirstVentury. The company's two lead clinical programs focus on the treatment of Hodgkin's disease and Non-Hodgkin's Lymphoma, respectively.

Share this